AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
3.18
+0.01 (+0.32%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.17
Open3.23
Bid2.90 x 500
Ask3.23 x 1500
Day's Range3.09 - 3.24
52 Week Range0.50 - 4.24
Volume1,886,599
Avg. Volume4,639,400
Market Cap488.43M
Beta1.25
PE Ratio (TTM)-5.11
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    AVEO Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AVEO) : October 18, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives AVEO Pharmaceuticals, Inc. a score of 7. Our analysis is based on comparing AVEO Pharmaceuticals, Inc. with the following peers – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., GTx, Inc., Bristol-Myers Squibb Company, Merrimack Pharmaceuticals, Inc., Amgen Inc. and Eli Lilly and Company (BIIB-US, REGN-US, ARQL-US, GTXI-US, ... Read more (Read more...)

  • Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
    Motley Fool4 days ago

    Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today

    Shares have seen increased volatility despite the company gaining its first-ever marketing approval recently.

  • AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017
    Capital Cube4 days ago

    AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AVEO Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Forbes16 days ago

    Two Techs And Two Biotechs Breaking Out

    Here are two biotech and two tech stocks that are breaking out technically.

  • MarketWatch16 days ago

    Harry Boxer’s four stocks that are breaking out this week

    In focus: Amicus Therapeutics, AVEO Pharmaceuticals, AXT and Dynavax Technologies.

  • Capital Cube25 days ago

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Should You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?
    Simply Wall St.last month

    Should You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?

    If you are a shareholder in AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Capital Cubelast month

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Here's Why AVEO Pharmaceuticals Lost as Much as 19% Today
    Motley Fool2 months ago

    Here's Why AVEO Pharmaceuticals Lost as Much as 19% Today

    On Monday, the biopharma announced drug approval in Europe. What's going on?

  • MarketWatch2 months ago

    AVEO Pharma stock rises 6% after cancer drug gets approved in Europe

    AVEO Pharmaceuticals Inc. shares rose as much as 6.2% to $4.01 in extremely heavy morning trade Monday after the company's cancer drug was approved in Europe. The drug, Fotivda, was approved for adults ...

  • Capital Cube2 months ago

    ETFs with exposure to AVEO Pharmaceuticals, Inc. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
    Capital Cube2 months ago

    AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017

    Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)

  • AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
    Zacks2 months ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

    AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

  • Associated Press2 months ago

    AVEO reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The cancer drug company posted revenue of $351,000 ...

  • AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
    Zacks3 months ago

    AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

    AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.

  • Here's Why AVEO Oncology Rose as Much as 15% Today
    Motley Fool3 months ago

    Here's Why AVEO Oncology Rose as Much as 15% Today

    The momo trading continues for AVEO Oncology stock -- this time with news from investment funds.

  • Zacks3 months ago

    Company News for July 10, 2017

    Companies in the News are: BRK.A,SPA,AVEO,ABCO,UNH

  • AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%
    Zacks3 months ago

    AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%

    AVEO Pharmaceuticals, Inc. (AVEO) shares rose around 15% in the last trading session.

  • InvestorPlace3 months ago

    Why AVEO Pharmaceuticals, Inc. (AVEO) Stock Is Soaring Today

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares skyrocketed early in the day on positive news regarding its cancer drug. The medication in question is tivozanib, which is being considered for approval in Europe. A scientific committee of the European Medicines Agency recommended the drug for approval and it will be considered by the European Commission.

  • 2 Biotech Stocks on Analysts’ Radar: Cara Therapeutics Inc (CARA) and AVEO Pharmaceuticals, Inc. (AVEO)
    SmarterAnalyst4 months ago

    2 Biotech Stocks on Analysts’ Radar: Cara Therapeutics Inc (CARA) and AVEO Pharmaceuticals, Inc. (AVEO)

    New insights emerge in the biotech sector as Cara Therapeutics Inc (NASDAQ:CARA) released mixed results from a phase 2b trial of the company's pain medication, and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has gained CHMP recommendation for its kidney cancer drug. Let’s take a closer look as analysts weigh in on both drug makers:

  • Here's Why AVEO Oncology Rose As Much As 13.8% Today
    Motley Fool4 months ago

    Here's Why AVEO Oncology Rose As Much As 13.8% Today

    AVEO Oncology stock also dropped as much as 12.3% in a wild trading session.

  • AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
    Zacks4 months ago

    AVEO's Kidney Cancer Candidate Gets CHMP Recommendation

    AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).

  • Reuters4 months ago

    EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

    European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market. The European Medicines Agency (EMA) said experts at its Committee for Medicinal Products for Human Use (CHMP) had backed the oral, once-daily drug for marketing approval as a first-line treatment for advanced renal cell carcinoma, or kidney cancer. The drug was also backed for treating adult patients with advanced kidney cancer who met certain criteria and had received one prior treatment with cytokine therapy, the EMA said.

  • AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
    Zacks4 months ago

    AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

    AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target